International Organization of Research & Development (IORD)
ISSN: 2348-0831
Vol 12 Issue 01 | 2024

Intellectual Property and 'The Lost Year' of COVID-19 Deaths: Equity, Vaccine Access, and IP Barriers

Sharda Beniwal (Ph.D Research Scholar)[1], Dr. Vijaymala (Associate Professor)[2]
Department – Law, Shri Jagdish Prasad Jhabarmal Tibrewala University, Chudela, Jhunjhunu

ABSTRACT

The year 2021—termed by some public health advocates as the "lost year" of the COVID-19 pandemic—witnessed millions of preventable deaths across the developing world due to stark inequalities in vaccine access. Despite rapid scientific advancements and mass vaccine production, patent monopolies, trade restrictions, and intellectual property (IP) barriers impeded timely and equitable distribution of vaccines to low- and middle-income countries. This paper explores the intersection of IP law and global health justice, analyzing how rigid patent protections under the TRIPS framework exacerbated the crisis. It discusses the ethical implications, failed legal mechanisms, and the urgency of IP reform to prevent another lost year in future pandemics.
Keywords: COVID-19, Intellectual Property Rights, Vaccine Equity, TRIPS, The Lost Year, Global Health Justice, IP Barriers, Public Health Law, Vaccine Nationalism, Patent Monopolies, Technology Transfer

1. INTRODUCTION

The COVID-19 pandemic exposed systemic failures not only in public health infrastructure but also in global legal and economic governance. While the rapid development of COVID-19 vaccines was a testament to the power of scientific collaboration and biotechnology, the distribution of those vaccines was anything but equitable. As wealthy countries secured the majority of doses through advance purchase agreements and stockpiling, large portions of the global population—especially in Africa, Asia, and Latin America—remained unvaccinated. This resulted in 2021 being labeled by several public health advocates as the **"lost year"**—a time when millions of lives could have been saved, had access to vaccines been governed by principles of justice rather than market exclusivity.

At the heart of this disparity lay the framework of intellectual property rights (IPRs)—specifically, the patent regimes enforced under the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). These rights gave pharmaceutical companies monopolistic control over the production and distribution of life-saving vaccines, diagnostics, and therapeutics. The TRIPS framework, while designed to protect innovation, ended up becoming a barrier to global health equity during the most significant health emergency in a century.

Countries like India and South Africa advocated for a temporary waiver of certain TRIPS provisions, but such efforts were delayed, diluted, and ultimately limited in scope. By the time the WTO adopted a partial waiver in 2022, the damage had already been done. Less than 2% of the population in low-income countries had received even a single dose by mid-2021, while high-income nations had begun administering third and fourth booster shots.

This paper examines the legal, ethical, and humanitarian consequences of the global IP regime during the COVID-19 crisis. It interrogates how patent monopolies, technology hoarding, and lack of knowledge transfer led to preventable deaths and prolonged the pandemic in developing countries. It further analyzes the failures of COVAX, limitations of TRIPS flexibilities, and the moral implications of vaccine nationalism. The study emphasizes that the suffering of 2021 was not a result of technological inadequacy, but of policy paralysis, legal rigidity, and economic protectionism.

In a world where pandemics are expected to become more frequent due to globalization and climate change, the lessons of this lost year must lead to structural reforms. Intellectual property laws must evolve from serving the interests of the few to protecting the lives of the many. This paper seeks to contribute to that evolution.

2. REVIEW OF LITERATURE

Scholarly and institutional literature surrounding intellectual property rights (IPRs) and COVID-19 has grown rapidly, reflecting growing global concerns about equity, vaccine nationalism, and the structural role of IP in health access. This section provides a chronological overview of key contributions that have shaped discourse and policy debates related to the global health crisis.

1. UN General Assembly (1948)
Article 25 of the Universal Declaration of Human Rights (UDHR) affirms the right of every individual to a standard of living adequate for health and well-being, including access to medical care. While it predates the COVID-19 crisis, it has been cited widely as a moral and legal foundation for health equity arguments during the pandemic.

2. WTO Doha Declaration (2001)
The Doha Declaration on TRIPS and Public Health reaffirmed the right of WTO members to protect public health and promote access to medicines. Though originally framed in response to the HIV/AIDS crisis, it laid critical legal groundwork for invoking TRIPS flexibilities like compulsory licensing—though these mechanisms proved sluggish during COVID-19.

3. Médecins Sans Frontières (2020)
In the early months of the pandemic, MSF strongly criticized the failure of voluntary licensing mechanisms and warned that IP protections would become barriers to life-saving medical innovation. They advocated for a broad, proactive TRIPS waiver and emphasized the risks of monopolized vaccine supply chains.

4. WHO (2021)
The World Health Organization released assessments of the global response and highlighted the limited participation of pharmaceutical firms in mechanisms like C-TAP and the mRNA technology transfer hub. WHO emphasized that IP barriers, lack of transparency, and corporate secrecy were key impediments to equitable vaccine access.

5. Gopakumar, K. (2021)
Writing for Third World Network, Gopakumar analyzed the dynamics of the India–South Africa TRIPS waiver proposal, arguing that Northern resistance was driven by the pharmaceutical industry's influence on trade policy. He noted the deep inequities in global governance and the overreliance on market-based distribution of medical technologies.

6. Watal, J. (2021)
In a WHO policy piece, Watal examined the inherent complexity of TRIPS flexibilities and argued that procedural delays, diplomatic pushbacks, and political asymmetries made compulsory licensing almost non-functional in emergency situations. She advocated for stronger global legal tools to ensure faster response mechanisms.

7. Correa, C. M. (2022)
In a comprehensive critique, Correa stated that the limited scope of the WTO's MC12 waiver decision was symbolic rather than effective. He argued that the exclusion of diagnostics and therapeutics, coupled with no technology transfer obligations, rendered the waiver largely ineffective in improving access in low-income countries.

8. Médecins Sans Frontières (2022)
A year after the waiver negotiations began, MSF reiterated that 2021 was a lost opportunity. Their report cited preventable deaths and suffering due to the delay and dilution of the waiver. They warned that failure to address IP issues now would replay similar tragedies in future pandemics.

9. South Centre (2022)
This intergovernmental organization emphasized that intellectual property monopolies during COVID-19 not only delayed equitable access but actively undermined public trust in international institutions. They called for a binding international treaty on pandemic preparedness with enforceable IP and access provisions.

3. OBJECTIVES OF THE STUDY

This study seeks to critically analyze the role of intellectual property rights (IPRs) in exacerbating global health inequities during the COVID-19 pandemic, particularly in 2021—described by many as the "lost year" in global vaccine equity. It aims to unravel how legal structures, political inertia, and institutional limitations collectively denied timely access to life-saving vaccines for millions in the Global South. The study is guided by the following key objectives:

1. To examine how IPRs under the TRIPS Agreement influenced access to COVID-19 vaccines and health technologies
This objective focuses on the legal structure of patents and trade secrets within the WTO's TRIPS framework, and how these mechanisms created practical barriers for low- and middle-income countries in acquiring or manufacturing vaccines, diagnostics, and therapeutics.

2. To assess the global distribution of COVID-19 vaccines during 2021 and the resulting public health consequences
The study aims to map vaccine access disparities, particularly highlighting how wealthy countries secured the majority of early supplies while the rest of the world waited. It explores the link between IP enforcement and global mortality gaps, especially in Africa, Latin America, and South Asia.

3. To analyze the international response to the TRIPS waiver proposal
This includes examining the India–South Africa waiver initiative, its global support and opposition, and the eventual limited outcome of the WTO MC12 decision. The study aims to identify the political and institutional reasons behind the failure to implement a robust, timely waiver.

4. To evaluate the moral and ethical implications of patent monopolies during a public health emergency
The paper investigates whether the commercial justifications for patent protection stood up to ethical scrutiny when millions were dying. It critically assesses arguments based on human rights, distributive justice, and the duty of care owed by states and corporations.

5. To identify and document the lessons of the 'Lost Year' for future global health crises
This objective seeks to generate actionable insights to ensure that global legal and policy frameworks are more prepared, responsive, and just in future pandemics. It asks: what should change in the IP system so that no life is lost due to policy failure again?

4. RESEARCH METHODOLOGY

This research adopts a **qualitative, doctrinal, and policy-oriented approach** to assess how intellectual property rights (IPRs) influenced global vaccine access during the COVID-19 pandemic—particularly in the year 2021. The study involves critical examination of international treaties, national laws, institutional reports, and scholarly literature to evaluate the **legal, ethical, and policy failures** of the existing IP system.

1. Nature of the Study
The research is **non-empirical and descriptive-analytical** in nature. It is aimed at:

- Understanding the structural role of IPRs within the global health architecture
- Analyzing legal texts and international policy documents
- Interpreting the ethical foundations of health rights and vaccine access

The focus is on **interpretation and normative evaluation**, rather than statistical measurement or field-based data collection.

2. Data Sources
Primary Sources:

- TRIPS Agreement (WTO, 1995) – Especially Articles 7, 8, 27, 31, and 73
- India–South Africa TRIPS Waiver Proposal (WTO/IP/C/W/669, 2020)
- WTO Ministerial Conference (MC12) Decision on TRIPS Waiver (2022)
- Universal Declaration of Human Rights (UDHR, 1948) – Article 25 on right to health
- Doha Declaration on TRIPS and Public Health (2001)

Secondary Sources:

- Reports and briefings from WHO, MSF, South Centre, Third World Network
- Articles from peer-reviewed journals on IP law, bioethics, and global public health
- News articles, opinion columns, and expert interviews from 2020–2023
- Country-level vaccination data from sources like Our World in Data, UNICEF, and GAVI

3. Methods of Analysis

- Legal and Doctrinal Analysis: Close reading of legal documents to assess the structure and limitations of IP law in pandemics.
- Comparative Policy Review: Cross-country comparison of waiver positions (supporting vs. opposing countries), and evaluation of voluntary vs. mandatory licensing outcomes.
- Ethical Evaluation: Use of normative theories—such as utilitarianism, equity theory, and human rights ethics—to assess the morality of IP enforcement.
- Thematic Categorization: Synthesizing data under themes like vaccine apartheid, waiver politics, technology monopolies, and structural global inequity.

4. Limitations of the Study

- The study is based on secondary data and textual interpretation, without conducting fieldwork or interviews.

- Some pharmaceutical licensing agreements are confidential, limiting full access to transparency.
- The situation remains dynamic, and newer data post-2023 may evolve the analysis.
- Focus is centered primarily on vaccine access, though therapeutics and diagnostics are acknowledged.

5. RESULTS AND DISCUSSION

The analysis of intellectual property rights (IPRs) and global vaccine access during the COVID-19 pandemic—particularly in 2021—reveals a pattern of institutional delay, policy failure, and moral disregard for global equity. The year came to be known as "The Lost Year" because millions of lives were lost due to delayed access to vaccines, despite their availability in the Global North. The discussion is organized thematically below:

1. Patent Barriers and Limited Global Production

The monopolistic structure of vaccine production was enabled by strong patent protections, especially for mRNA technology. Companies like Pfizer-BioNTech and Moderna held exclusive rights to their innovations, backed by TRIPS-compliant IP laws. As a result:

- Generic manufacturers in the Global South were legally restricted from producing vaccines.
- Technology transfer was non-mandatory, leading to underutilization of global manufacturing capacity.
- Many capable producers (e.g., in India, South Africa, Brazil) remained on standby due to lack of legal access.

This bottleneck artificially limited global supply and prolonged the duration of vulnerability in low-income nations.

2. Delay and Dilution of the TRIPS Waiver

India and South Africa proposed a temporary waiver from TRIPS obligations in October 2020. However:

- It faced fierce opposition from high-income countries, including the EU, UK, Switzerland, and Japan.
- WTO procedures delayed the decision for over 18 months.
- The final waiver, adopted in June 2022, covered only vaccines, excluding therapeutics and diagnostics.

By the time the waiver was agreed upon, the worst phase of the pandemic had already passed, and the waiver's practical benefit had largely eroded. This reflected a failure of global governance to act in real time.

3. Vaccine Nationalism and Hoarding

In 2021, high-income nations:

- Signed advance purchase agreements (APAs) with vaccine companies, monopolizing early supply.
- Administered booster doses even before many in the Global South received a first shot.
- Stockpiled unused doses while millions died elsewhere.

This behavior, often termed "vaccine apartheid", was made possible by the market-based nature of vaccine distribution backed by IP monopolies. It contradicted WHO's principle of equitable allocation.

4. Failure of Voluntary Mechanisms

Initiatives like COVAX and C-TAP were supposed to bridge the equity gap. However:

- Pharmaceutical companies largely refused to join the WHO's C-TAP platform for knowledge sharing.
- Voluntary licenses were limited, non-transparent, and favored select partners.
- COVAX was underfunded and oversold, failing to deliver on its promise.

Without mandatory global mechanisms, these voluntary efforts fell far short of addressing the crisis.

5. Ethical Crisis of the IP Regime

The enforcement of IP rights during the pandemic raised severe ethical concerns:

- Publicly funded vaccines (like Moderna's, largely US government–funded) were commercialized without affordability guarantees.
- Patents were prioritized over people, undermining the right to life and health enshrined in international law.
- The waiver delays directly contributed to avoidable mortality, especially in Africa, where vaccination rates in 2021 were below 10%.

The pandemic revealed that the current IP system, while legally sound, is morally deficient in times of global emergencies.

6. India's Unused Legal Tools

Despite being a leader in global vaccine manufacturing and co-sponsoring the TRIPS waiver, India:

- Did not issue any compulsory license under its Patents Act (Sections 84 and 92).
- Relied on voluntary arrangements and public–private partnerships.
- Showed caution in asserting domestic legal flexibilities, possibly due to global trade pressures.

6. RECOMMENDATIONS

The inequities observed during the COVID-19 pandemic—and especially during the so-called "Lost Year" of 2021—reveal deep structural flaws in how intellectual property rights (IPRs) are prioritized over public health. To prevent the repetition of such failures in future global crises, the following recommendations are proposed:

1. Establish Pre-Negotiated Pandemic IP Waiver Protocols
There is a need for a predefined legal mechanism under the WTO or WHO that:

- Automatically activates IP waivers during declared public health emergencies
- Covers the full spectrum of medical products: vaccines, diagnostics, therapeutics, raw materials, and delivery platforms
- Avoids lengthy negotiations and delays through a binding multilateral framework

Such a mechanism would save time, lives, and global trust in future health crises.

2. Legally Mandate Technology Transfer and Data Sharing
IP waivers are ineffective without access to:

- Manufacturing protocols
- Clinical trial data
- Cold-chain and packaging technology

Multilateral agreements must compel pharmaceutical firms to share know-how, especially when public funding underwrites R&D. Public health cannot rely solely on goodwill.

3. Revise the TRIPS Agreement to Prioritize Human Rights
The TRIPS Agreement must be amended or interpreted to:

- Explicitly recognize the right to health
- Embed mandatory flexibilities for emergencies
- Provide for independent review mechanisms in case of state-to-state IP disputes related to health

This would realign WTO law with humanitarian and ethical obligations.

4. Make Voluntary Licensing Transparent and Equitable
If voluntary mechanisms like COVAX, C-TAP, or MPP are to remain viable:

- All license agreements must be publicly disclosed
- They must be non-exclusive, geographically inclusive, and time-bound
- Civil society and LMIC stakeholders must be included in oversight

Transparency will reduce corporate control and strategic gatekeeping of lifesaving technology.

5. Support Regional Manufacturing Hubs
Global health infrastructure must decentralize by:

- Strengthening regional mRNA hubs (e.g., in Africa, South America, South Asia)
- Supporting public-sector pharmaceutical production
- Funding local R&D to reduce dependency on Global North innovations

This builds sovereignty and resilience in low- and middle-income countries.

6. Align Domestic Patent Laws with Emergency Readiness
Countries like India must:

- Simplify procedural barriers to compulsory licensing
- Clearly define emergency triggers in national IP laws
- Ensure that domestic patent offices are trained to respond quickly during global crises

This bridges the gap between international commitments and national execution.

7. Promote Global Treaty on Health and IP
A global treaty should be negotiated under the WHO Pandemic Accord or as a new UN instrument, focusing on:

- Mandatory IP waivers during declared pandemics
- Global vaccine allocation principles
- Legal sanctions for non-compliance by states or corporations

Such a treaty would correct the voluntary and fragmented nature of current frameworks.

8. Embed Ethics in Global Trade and IP Governance
Lastly, global institutions like WTO, WIPO, and WHO must:

- Include bioethics experts and public health voices in IP policy formulation
- Conduct health equity impact assessments before approving trade deals

- Shift from profit-driven models to solidarity-based frameworks

7. CONCLUSION

The COVID-19 pandemic, particularly during the year 2021, exposed profound inequalities in the global health system. The development of life-saving vaccines within record time was a historic scientific triumph, but their distribution reflected a deep failure of global justice and legal responsiveness. Intellectual property rights (IPRs), as embedded in the TRIPS framework, were meant to incentivize innovation—but during a global health emergency, they became barriers to access, especially for the Global South.

The concept of the "Lost Year" is not merely rhetorical—it is grounded in the avoidable deaths, prolonged infections, and social-economic devastation that disproportionately afflicted low- and middle-income countries due to delayed vaccine access. This delay was not due to scientific or logistical inability but due to policy paralysis, legal rigidity, and the prioritization of market monopolies over moral imperatives.

While India and South Africa's waiver proposal represented a bold move towards equity, its delay and dilution reflected the institutional shortcomings of the WTO and the disproportionate influence of high-income nations and pharmaceutical corporations. The ultimate waiver was narrow in scope, untimely in execution, and lacked enforceable obligations for technology sharing—thus failing to deliver the global solidarity it promised.

This study demonstrates that voluntary licensing, COVAX, and corporate philanthropy cannot substitute for legally binding, ethically grounded frameworks. The current IP regime, even with its embedded flexibilities, is inadequate in addressing the moral urgency of pandemics. The human cost of maintaining commercial exclusivity during a crisis cannot be justified in any ethically coherent global order.

Moving forward, the international community must rethink how IPRs are governed in emergencies. Public health must be embedded as a non-negotiable legal and moral priority in trade and IP systems. Governments, international institutions, and civil society must work together to build a system where life-saving technologies are treated as global public goods, not private commodities.

In conclusion, the pandemic has given the world a painful but essential lesson: intellectual property cannot be above human life. To prevent future "lost years," we must ensure that innovation is coupled with equity, ethics, and enforceable global responsibility.

8. REFERENCES

1. WHO. (2021). Global COVID-19 Vaccination Equity Report
2. WTO. (2022). TRIPS Waiver and Ministerial Conference Proceedings
3. Médecins Sans Frontières. (2021). The Real Barriers to Vaccine Access
4. Correa, C. M. (2021). Public Health and IP Rights: Beyond the TRIPS Waiver
5. Gopakumar, K. M. (2022). "The IP Crisis During the Pandemic" – Third World Network
6. The Patents Act, 1970 (India)
7. UN. (1948). Universal Declaration of Human Rights
8. WHO. (2020). COVID-19 Technology Access Pool (C-TAP)
9. MSF Access Campaign. (2022). "Missed Opportunities in mRNA Tech Transfer"
10. The Lancet. (2021). "Vaccine Apartheid and Global Justice"